The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
TCT 2021 | Healthcare utilization & end of life outcomes in patients receiving CAR-T
Connor Johnson
• 5 Feb 2021
Connor Johnson, MD, Massachusetts General Hospital & Harvard Medical School, Boston, MA, outlines the results of a retrospective analysis evaluating the impact of CAR T-cell therapy on healthcare utilization and end-of-life outcomes. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
